Imaging markers of disease progression in multiple system atrophy

Different neuroimaging modalities hold potential as surrogate markers of underlying neurodegeneration in multiple system atrophy (MSA) and may reflect cell loss, altered glucose metabolism, microglial proliferation, astroglial activation, and nigrostriatal denervation. Multiple studies have demonstrated that serial structural and functional imaging studies are capable of demonstrating neurodegeneration in MSA patients quantitatively, which allows sample size estimates based on rates of progression of these neuroimaging markers. This review summarizes recent research findings as a tool to assess longitudinal changes of serial neuroimaging-derived parameters in MSA.

[1]  Y. Sohn,et al.  Mesenchymal stem cells can modulate longitudinal changes in cortical thickness and its related cognitive decline in patients with multiple system atrophy , 2014, Front. Aging Neurosci..

[2]  M. T. Pellecchia,et al.  Progression of striatal and extrastriatal degeneration in multiple system atrophy: A longitudinal diffusion‐weighted MR study , 2011, Movement disorders : official journal of the Movement Disorder Society.

[3]  S. Gilman,et al.  Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial , 2014, The Lancet Neurology.

[4]  W. Poewe,et al.  Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  D. Maraganore,et al.  Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990 , 1997, Neurology.

[6]  G. Barker,et al.  Whole-Brain Atrophy Rate in Idiopathic Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy , 2016, Parkinson's disease.

[7]  D. Mikulis,et al.  Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. , 2014, Parkinsonism & related disorders.

[8]  A. Strafella,et al.  Imaging insights into basal ganglia function, Parkinson's disease, and dystonia , 2014, The Lancet.

[9]  Albert C. Ludolph,et al.  Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALE , 2011, PloS one.

[10]  K. Oba,et al.  Comparison of Different Symptom Assessment Scales for Multiple System Atrophy , 2015, The Cerebellum.

[11]  W. Poewe,et al.  Therapeutic advances in multiple system atrophy and progressive supranuclear palsy , 2015, Movement disorders : official journal of the Movement Disorder Society.

[12]  Christian Kremser,et al.  Progression of putaminal degeneration in multiple system atrophy: A serial diffusion MR study , 2006, NeuroImage.

[13]  K. Seppi,et al.  Structural Imaging in Atypical Parkinsonism. , 2018, International review of neurobiology.

[14]  W. Poewe,et al.  Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. , 2019, Parkinsonism & related disorders.

[15]  Nick C Fox,et al.  Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. , 2006, Brain : a journal of neurology.

[16]  S. Gilman,et al.  Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial , 2015, The Lancet Neurology.

[17]  M. Schocke,et al.  Significance of MRI in Diagnosis and Differential Diagnosis of Parkinson’s Disease , 2010, Neurodegenerative Diseases.

[18]  Y Ben-Shlomo,et al.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study , 1999, The Lancet.

[19]  K. Seppi,et al.  Magnetic resonance imaging for the diagnosis of Parkinson’s disease , 2017, Journal of Neural Transmission.

[20]  Nick C Fox,et al.  Serial volumetric MRI in Parkinsonian disorders , 2009, Movement disorders : official journal of the Movement Disorder Society.

[21]  Nick C Fox,et al.  Delineating the sites and progression of in vivo atrophy in multiple system atrophy using fluid‐registered MRI , 2003, Movement disorders : official journal of the Movement Disorder Society.

[22]  A. Toga,et al.  Callosal tissue loss in multiple system atrophy—A one‐year follow‐up study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[23]  G. Wenning,et al.  RARE DISEASES: Multiple system atrophy: insights into a rare and debilitating movement disorder , 2017 .

[24]  K. Seppi,et al.  Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies , 2016, Movement disorders : official journal of the Movement Disorder Society.

[25]  Michael Schocke,et al.  Progression of brain atrophy in multiple system atrophy , 2007, Journal of Neurology.

[26]  Nick C Fox,et al.  Regional brain volumes distinguish PSP, MSA‐P, and PD: MRI‐based clinico‐radiological correlations , 2006, Movement disorders : official journal of the Movement Disorder Society.

[27]  Nick C Fox,et al.  MRI derived brain atrophy in PSP and MSA-P , 2007, Journal of neurology.

[28]  J. Jankovic,et al.  Natural History of Multiple System Atrophy in North America: A Prospective Cohort Study , 2015, The Lancet Neurology.

[29]  Günther Deuschl,et al.  The natural history of multiple system atrophy: a prospective European cohort study , 2013, The Lancet Neurology.

[30]  Y. Sohn,et al.  A randomized trial of mesenchymal stem cells in multiple system atrophy , 2012, Annals of neurology.

[31]  Alexander Gerhard,et al.  Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) , 2010, Movement disorders : official journal of the Movement Disorder Society.